See more : CHATHA Foods Limited (CHATHA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Seer, Inc. (SEER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seer, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Home Consortium Limited (HMC.AX) Income Statement Analysis – Financial Results
- Burberry Group plc (BURBY) Income Statement Analysis – Financial Results
- Pediatrix Medical Group, Inc. (MD) Income Statement Analysis – Financial Results
- Super Fine Knitters Limited (SKL.BO) Income Statement Analysis – Financial Results
- Creative Technology Ltd (C76.SI) Income Statement Analysis – Financial Results
Seer, Inc. (SEER)
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.18M | 14.69M | 6.39M | 656.00K | 58.00K | 0.00 |
| Cost of Revenue | 8.16M | 7.94M | 3.21M | 0.00 | 701.00K | 100.00K |
| Gross Profit | 7.03M | 6.74M | 3.19M | 656.00K | -643.00K | -100.00K |
| Gross Profit Ratio | 46.29% | 45.91% | 49.87% | 100.00% | -1,108.62% | 0.00% |
| Research & Development | 53.02M | 45.80M | 29.12M | 18.94M | 12.39M | 3.78M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 15.36M | 4.61M | 2.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 58.95M | 58.53M | 45.76M | 15.36M | 4.61M | 2.98M |
| Other Expenses | 0.00 | -351.00K | -223.00K | -9.00K | -58.00K | 0.00 |
| Operating Expenses | 111.97M | 103.98M | 74.66M | 34.31M | 16.94M | 6.76M |
| Cost & Expenses | 120.12M | 111.92M | 77.87M | 34.31M | 16.94M | 6.76M |
| Interest Income | 17.76M | 4.60M | 326.00K | 883.00K | 850.00K | 451.00K |
| Interest Expense | 0.00 | 327.00K | 22.00K | 9.00K | 5.00K | 0.00 |
| Depreciation & Amortization | 5.58M | 5.90M | 3.56M | 1.61M | 701.00K | 100.00K |
| EBITDA | -97.89M | -93.29M | -68.59M | -31.17M | -15.33M | -6.21M |
| EBITDA Ratio | -644.74% | -633.07% | -1,112.72% | -4,994.82% | -26,434.48% | 0.00% |
| Operating Income | -103.46M | -97.24M | -71.47M | -33.65M | -16.88M | -6.76M |
| Operating Income Ratio | -681.48% | -662.14% | -1,117.81% | -5,129.42% | -29,108.62% | 0.00% |
| Total Other Income/Expenses | 17.19M | 4.27M | 304.00K | 874.00K | 845.00K | 451.00K |
| Income Before Tax | -86.28M | -92.97M | -71.17M | -32.78M | -16.04M | -6.31M |
| Income Before Tax Ratio | -568.28% | -633.07% | -1,113.06% | -4,996.19% | -27,651.72% | 0.00% |
| Income Tax Expense | 0.00 | -4.27M | -2.54M | -1.61M | 5.00K | 451.00K |
| Net Income | -86.28M | -88.70M | -68.63M | -31.17M | -16.04M | -6.31M |
| Net Income Ratio | -568.28% | -604.00% | -1,073.40% | -4,751.37% | -27,660.34% | 0.00% |
| EPS | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| EPS Diluted | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| Weighted Avg Shares Out | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
| Weighted Avg Shares Out (Dil) | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Seer to Participate in Upcoming November Investor Conferences
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Seer Appoints Nicolas Roelofs to its Board of Directors
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports